This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Sep;14(10):916-7.

doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22.

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Jacek Jassem¹, Rafał Dziadziuszko

Affiliations

PMID: 23883923
DOI: 10.1016/S1470-2045(13)70352-8

Comment

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Jacek Jassem et al. Lancet Oncol. 2013 Sep.

. 2013 Sep;14(10):916-7.

doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22.

Authors

Jacek Jassem¹, Rafał Dziadziuszko

Affiliation

¹ Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80 211 Gdańsk, Poland. jjassem@gumed.edu.pl

PMID: 23883923
DOI: 10.1016/S1470-2045(13)70352-8

No abstract available

PubMed Disclaimer

Comment on

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.

Similar articles

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R, Subramanian J. Govindan R, et al. Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K. Takeda M, et al. Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28. Jpn J Clin Oncol. 2012. PMID: 22457323
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX, Fu S, Zhang Q, Guo XM. Qi WX, et al. Curr Med Res Opin. 2015 Jan;31(1):25-33. doi: 10.1185/03007995.2014.978448. Epub 2014 Oct 30. Curr Med Res Opin. 2015. PMID: 25329826 Review.

See all similar articles

Cited by

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA. Smith DL, et al. Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1. Target Oncol. 2015. PMID: 25077897 Free PMC article.
A rotamer relay information system in the epidermal growth factor receptor-drug complexes reveals clues to new paradigm in protein conformational change.
Hameduh T, Mokry M, Miller AD, Adam V, Heger Z, Haddad Y. Hameduh T, et al. Comput Struct Biotechnol J. 2021 Sep 27;19:5443-5454. doi: 10.1016/j.csbj.2021.09.026. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34667537 Free PMC article.
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.
Thomas R, Weihua Z. Thomas R, et al. Front Oncol. 2019 Aug 23;9:800. doi: 10.3389/fonc.2019.00800. eCollection 2019. Front Oncol. 2019. PMID: 31508364 Free PMC article.
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Cheng Y, Zhang T, Xu Q. Cheng Y, et al. MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec. MedComm (2020). 2021. PMID: 34977873 Free PMC article. Review.
MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer.
Li J, Wang H, Ke H, Ni S. Li J, et al. Tumour Biol. 2015 Aug;36(8):5785-90. doi: 10.1007/s13277-015-3247-z. Epub 2015 Feb 26. Tumour Biol. 2015. PMID: 25716201

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal